Herdon Christopher M
Division of Clinical Affairs, Ortho-McNeil Pharmaceutical, O'Fallon, IL, USA.
J Neurosci Nurs. 2003 Dec;35(6):321-6.
Chronic malignant pain is experienced by as many as 80% of patients with cancer. While these patients may experience either nociceptive or neuropathic pain, oftentimes a mixed presentation is encountered. Nociceptive pain may respond to opioid and nonopioid analgesics, while antidepressants and antiepileptics may be beneficial for neurogenic pain. New evidence points to efficacy of opioids for neuropathic, in addition to nociceptive pain syndromes, further clarifying the use of these agents for this patient population. When used properly, opioids are a safe and effective tool for the management of cancer pain.
多达80%的癌症患者会经历慢性恶性疼痛。虽然这些患者可能经历伤害性疼痛或神经性疼痛，但通常会遇到混合性表现。伤害性疼痛可能对阿片类和非阿片类镇痛药有反应，而抗抑郁药和抗癫痫药可能对神经源性疼痛有益。新证据表明，除了伤害性疼痛综合征外，阿片类药物对神经性疼痛也有效，这进一步明确了这些药物在该患者群体中的应用。正确使用时，阿片类药物是治疗癌症疼痛的安全有效工具。
